# Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

> **NCT02034474** · PHASE4 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 59 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02034474
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2017-02-06
- **Final completion:** 2017-02-06
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034474, "Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02034474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*